NgenBio Reports Q1 Revenue of 4.1 Billion KRW, Up 277% YoY
[Asia Economy Reporter Moon Hyewon] On the 27th, EnGen Bio announced that its sales revenue for the first quarter of this year reached 4.15 billion KRW.
This represents a 277% increase compared to the same period last year.
Operating loss was recorded at 1.72 billion KRW.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- "If Both Spouses Work There, How Much Would They Make?" "They Earn More Than Me, and I'm a Doctor"... Envy Erupts Over Samsung Electronics' Bonus
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "Going to Work Every Day Is Terrifying"... Starbucks Frontline Workers Vent Frustration Amid 'Tank Day' Backlash
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
An EnGen Bio official stated, "In preparation for the growth of the NGS precision diagnostics market in the post-COVID-19 era this year, we plan to focus on expanding export item approvals through active overseas market development," adding, "Through investment in a local CLIA Lab in the United States, we will establish a foothold to enter the US market, the world's largest market."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
